TOPIGEN Pharmaceuticals Inc, Montreal, has announced that the company will speak on its three lead clinical product candidates at two medical conferences in October. Two presentations are scheduled for The European Respiratory Society (ERS) 18th Annual Congress, and one presentation is scheduled for The Oligonucleotide Therapeutics Society (OTS) 4th Annual Meeting.
TOPIGEN will be presenting information on its two lead drug candidates: TPI ASM8 for asthma and TPI 1020 for COPD. Currently, both drug candidates are in Phase II studies. The company will also provide information on TPI 1100, a drug candidate for COPD that is in Phase I studies.
The first presentation at ERS is titled "Safety, Efficacy and Pharmacokinetics of Inhaled TPI 1020 in Smokers with Asthma" and will be presented by Louis-Philippe Boulet (principle investigator), on Tuesday, October 7. The second ERS presentation titled “Advantageous Toxicity Profile of Novel Inhaled Antisense Oligonucleotides, TPI ASM8 and TPI 1100, Following Chronic Dosing in Monkeys" will be also be presented on October 7, and will be lead by Nicolay Ferrari, PhD, director, pharmacology, TOPIGEN Pharmaceuticals. Ferrari will also present the OTS lecture titled, "TPI 1100: A Novel Inhaled FANA-containing Antisense Oligonucleotide Product Against Phosphodiesterase 4 and 7 for the Treatment of COPD," on Friday, October 17.
